Cazavi Injection Cazavi contains a combination of Ceftazidime, a third-generation cephalosporin, and Avibactam, a non-β-lactam β-lactamase inhibitor. Ceftazidime exerts bactericidal activity by binding to essential penicillin-binding proteins (PBPs), inhibiting bacterial cell wall peptidoglycan synthesis. Avibactam protects Ceftazidime from degradation by inactivating Ambler class A (e.g., KPC, CTX-M), class C (AmpC), and certain class D (e.g., OXA-48) β-lactamases. Cazavi® is indicated for the treatment of complicated intra-abdominal infections (cIAI), complicated urinary tract infections (cUTI) including pyelonephritis, hospital-acquired pneumonia (HAP) including ventilator-associated pneumonia (VAP), and infections caused by aerobic Gram-negative organisms in patients with limited treatment options.